Latigo Raises $150m To Drive Its First Pain Drug Toward Phase III

Series B Proceeds Will Fund Three NaV1.8 Candidates

 
• By Mandy Jackson
  
Latigo has three NaV1.8 inhibitors and an ASIC inhibitor in development (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Scrip